Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Behzad Aghazadeh

Page 1 of 7

Mirati Therapeutics Inc. (NASDAQ:MRTX): Behzad Aghazadeh’s VenBio Select Advisor filed an amended 13D.

You can check out VenBio Select Advisor’s latest holdings and filings here.

Please follow VenBio Select Advisor (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about VenBio Select Advisor or update its stock holdings.

Behzad Aghazadeh
Behzad Aghazadeh
venBio Select Advisor

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
venBio Select Advisor 3,748,101 0 3,748,101 0 3,748,101 14.99%
Behzad Aghazadeh 3,748,101 0 3,748,101 0 3,748,101 14.99%
Behzad Aghazadeh
Behzad Aghazadeh
venBio Select Advisor

Page 1 of 7 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*

Mirati Therapeutics,
Inc.

(Name of Issuer)

Common Stock,
$0.001 par value

(Title of Class of Securities)

60468T105

(CUSIP Number)

September
30, 2017

(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
þ Rule 13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page
1 of 7 Pages)

______________________________

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act“) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Mirati Therapeutics Inc. (NASDAQ:MRTX)
Trade (NASDAQ:MRTX) Now!
Page 1 of 7
Loading...